What is the 13F Pro Quality Score for AVAH?

13F Pro ranks Aveanna Healthcare Holdings, Inc. (AVAH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AVAH's current score at https://13fpro.ai/research/AVAH (free sign-up required for the full ranking).

Where does 13F Pro source AVAH data?

All Aveanna Healthcare Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Aveanna Healthcare Holdings, Inc. files with the SEC under CIK 1832332. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AVAH in?

Aveanna Healthcare Holdings, Inc. (AVAH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AVAH research updated on 13F Pro?

AVAH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aveanna Healthcare Holdings, Inc.(AVAH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1832332 AVAH stock profile & AI dashboard →

13F Pro Quality Score

59.2/100

Rank #935 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

70.8/100

Profitability

64.1/100

Balance Sheet

66.8/100

Earnings Quality

30.0/100

Free Cash Flow

45.5/100

Institutional Flow

24.6/100

Revenue Scale

65.6/100

Dilution Risk

56.5/100

AVAH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aveanna Healthcare Holdings, Inc. (AVAH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVAH at 59.2/100 on a 32-signal composite quality model, placing it at rank #935 of 2,879 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (24.6) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Aveanna Healthcare Holdings, Inc. reports quarterly revenue of $647.9M, net income of $41.7M, an operating margin of 10.7%. Top institutional holders of AVAH by reported 13-F value include BAIN CAPITAL INVESTORS, J.H. Whitney Equity Partners VII,, Nut Tree Capital Management,, based on the most recent SEC filings. AVAH trades on the Nasdaq exchange and files with the SEC under CIK 1832332. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVAH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aveanna Healthcare Holdings, Inc. directly from SEC EDGAR. Aveanna Healthcare Holdings, Inc.'s 13F Pro composite quality score has ranged between 30 and 59 since 2022, currently 59.2 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.

Revenue

Q1 2026

$647.9M

Net Income

Q1 2026

$41.7M

Free Cash Flow

Q1 2026

$4.3M

Operating Margin

Q1 2026

10.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+28.4% YoY

$2.43BFY 2025

FY21 $1.68BFY22 $1.79BFY23 $1.90BFY25 $2.43B

Net Income

+167381.7% YoY

$225.0MFY 2025

FY21 $-117.0MFY22 $-662.0MFY23 $-134.5KFY25 $225.0M

Operating Income

+3077.2% YoY

$256.5MFY 2025

FY21 $-36.1MFY22 $-642.3MFY23 $8.1MFY25 $256.5M

EPS (Diluted)

+247.9% YoY

$1.05FY 2025

FY21 $-0.69FY22 $-3.57FY23 $-0.71FY25 $1.05

Total Assets

+24.8% YoY

$2.01BFY 2025

FY21 $2.33BFY22 $1.71BFY23 $1.61BFY25 $2.01B

Total Debt

+1.4% YoY

$1.31BFY 2025

FY21 $1.24BFY22 $1.30BFY23 $1.29BFY25 $1.31B

Op. Cash Flow

+455.1% YoY

$125.9MFY 2025

FY21 $-11.3MFY22 $-48.4MFY23 $22.7MFY25 $125.9M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$2.43B +28.4%	$1.90B +6.0%	$1.79B +6.5%	$1.68B +12.3%	$1.50B +8.0%	$1.38B
Net Income	$225.0M +167381.7%	$-134.5K +100.0%	$-662.0M -465.6%	$-117.0M -105.2%	$-57.0M +25.4%	$-76.5M
Operating Income	$256.5M +3077.2%	$8.1M +101.3%	$-642.3M -1678.6%	$-36.1M -935.6%	$-3.5M -109.0%	$39.0M
EPS (Diluted)	$1.05 +247.9%	$-0.71 +80.1%	$-3.57 -417.4%	$-0.69	—	—
Total Assets	$2.01B +24.8%	$1.61B -5.8%	$1.71B -26.7%	$2.33B +26.6%	$1.84B	—
Total Debt	$1.31B +1.4%	$1.29B -0.4%	$1.30B +4.5%	$1.24B +5.1%	$1.18B	—
Operating Cash Flow	$125.9M +455.1%	$22.7M +146.8%	$-48.4M -326.4%	$-11.3M -109.7%	$116.6M +1438.3%	$-8.7M

AI Insight: AVAH Financial Trends

Revenue growth accelerating to 10% YoY while operating margins expanded and equity swung from negative $119M to positive $240M.

• Revenue grew 28% from Q2 2024 ($505M) to Q2 2026 ($648M); latest quarter shows 10% YoY growth vs Q2 2025 ($590M).

• Operating income surged 86% from Q2 2024 ($37M) to Q2 2026 ($69M); operating margin improved to 10.6% in Q2 2026.

• Shareholder equity turned positive, rising from negative $119M in Q2 2024 to positive $240M in Q2 2026.

⚠ Operating cash flow highly volatile; swung from $52M (Q2 2025) to $4M (Q2 2026), down 92% YoY.

⚠ Total debt relatively flat around $1.3B despite equity improvement; leverage still material relative to operating income.

AI Insight: AVAH Ratio Trends

Operating margin stabilized at 10.7% in Q2 2026 after Q3 2025 dip, while ROIC recovered to 17.9% and debt-to-equity tightened to 5.46x.

• Operating margin rebounded from 8.6% in Q3 2025 to 10.7% in Q2 2026, approaching the 13.6% peak achieved in Q2 2025.

• ROIC recovered to 17.9% in Q2 2026 from 16.2% in Q3 2025, though below Q2 2025's 25.1% high.

• Net profit margin improved to 6.4% in Q2 2026 from 2.3% in Q3 2025, strongest in trailing twelve months.

⚠ Q2 2025 posted exceptional 25.1% ROIC; Q2 2026 at 17.9% suggests normalization or operational headwinds.

⚠ D/E ratio remained elevated at 5.46x in Q2 2026; leverage reduction progress stalled since Q1 2026's 6.75x.

Get alerted when AVAH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aveanna Healthcare Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AVAH

BAIN CAPITAL INVESTORS LLC
$525.5M81,600,880 sh
J.H. Whitney Equity Partners VII, LLC
$233.4M36,242,631 sh
Nut Tree Capital Management, LP
$83.2M12,922,649 sh
BlackRock, Inc.
$35.4M5,500,912 sh
SUMMIT PARTNERS L P
$35.1M5,451,422 sh
VANGUARD CAPITAL MANAGEMENT LLC
$25.6M3,974,819 sh
Boston Partners
$18.2M2,824,074 sh
BRAIDWELL LP
$14.2M2,203,506 sh
LITTLEJOHN & CO LLC
$14.2M2,203,362 sh
Nuveen, LLC
$14.1M2,194,783 sh

Fund	Value	Shares
BAIN CAPITAL INVESTORS LLC	$525.5M	81,600,880
J.H. Whitney Equity Partners VII, LLC	$233.4M	36,242,631
Nut Tree Capital Management, LP	$83.2M	12,922,649
BlackRock, Inc.	$35.4M	5,500,912
SUMMIT PARTNERS L P	$35.1M	5,451,422
VANGUARD CAPITAL MANAGEMENT LLC	$25.6M	3,974,819
Boston Partners	$18.2M	2,824,074
BRAIDWELL LP	$14.2M	2,203,506
LITTLEJOHN & CO LLC	$14.2M	2,203,362
Nuveen, LLC	$14.1M	2,194,783

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AVAH on your watchlist

Track score changes the day Aveanna Healthcare Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AVAH a good stock to buy?

13F Pro's AI-powered analysis of Aveanna Healthcare Holdings, Inc. (AVAH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVAH are available on the AVAH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AVAH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVAH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aveanna Healthcare Holdings, Inc.'s investment landscape.